Metoclopramide on Gastric Emptying in Mechanically Ventilated Patients
NCT ID: NCT05641051
Last Updated: 2023-06-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
80 participants
INTERVENTIONAL
2022-12-14
2023-06-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating Neostigmine Effect on Reducing Gastric Residual Volume as Compared With Metoclopramide and Ondansetron
NCT05342818
A Comparative Evaluation of Mosapride Versus Metoclopramide for Enteral Feeding Intolerance in Critically Ill Patients
NCT06826443
The Efficacy of B6 and Metoclopramide Combination in Comparison With the Other Antiemetics
NCT06390787
Effect of Metoclopramide Versus Erythromycin on on Gastric Residual Volume
NCT04682691
Intrathecal Atropine vs IV Metoclopramide for Nausea & Vomiting During CS
NCT03932578
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Metoclopramide group
Patients will receive 10 mg intravenous metoclopramide / 6 hours.
Metoclopramide
Cases will receive 10 mg intravenous metoclopramide every 6 hours.
Control group
Patients will receive the same volume of intravenous placebo / 6 hours.
Placebo
Cases will receive the same volume of IV placebo / 6 hours.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Metoclopramide
Cases will receive 10 mg intravenous metoclopramide every 6 hours.
Placebo
Cases will receive the same volume of IV placebo / 6 hours.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Either gender.
3. Mechanically ventilated head trauma patients.
4. Patients receiving enteral feeding via nasogastric tube.
Exclusion Criteria
2. Patients with extrapyramidal manifestations.
3. Patients with known allergy to metoclopramide.
4. Patients with seizures.
5. Patients with renal or hepatic diseases.
20 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Khadija Mohammed Elbaradei
Resident of Anesthesia, Surgical Intensive Care and Pain Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tanta University Hospitals
Tanta, ElGharbiaa, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
35298/2/22
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.